POSC49 The Cost-Effectiveness of Brentuximab Vedotin in Frontline Systemic Anaplastic Large Cell Lymphoma in France

Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.454
https://www.valueinhealthjournal.com/article/S1098-3015(21)02249-X/fulltext
Title : POSC49 The Cost-Effectiveness of Brentuximab Vedotin in Frontline Systemic Anaplastic Large Cell Lymphoma in France
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02249-X&doi=10.1016/j.jval.2021.11.454
First page :
Section Title :
Open access? : No
Section Order : 11226
Categories :
Tags :
Regions :
ViH Article Tags :